Control
Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies.
Recent:Mourad.
May 24 |
Ensovibep for COVID-19: real-time meta analysis of 2 studies | |
| Significantly lower risk is seen for hospitalization. One study shows significant benefit. Meta analysis using the most serious outcome reported shows 47% [-108‑87%] lower risk, without reaching statistical significance. Early .. | ||
Feb 6 |
et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2025.02.002 | Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial |
| 28% lower mortality (p=0.16) and 11% lower combined mortality/hospitalization (p=0.47). Analysis of 2,311 hospitalized COVID-19 patients from four randomized controlled trials (ACTIV-3/TICO) showing no significant difference in long-term mortality with sotrovimab, amubarvimab/romlusevimab, tixagevimab-cilgavimab, or ensovibep. | ||
May 3 2024 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofae233 | The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study |
| 89% lower mortality (p=0.06), 78% fewer combined hospitalization/ER visits (p=0.02), 87% lower hospitalization (p=0.01), and 87% improvement (p=0.01). RCT 407 mild to moderate COVID-19 outpatients showing faster viral clearance, lower risk of hospitalization/ER visits, and shorter time to sustained recovery with ensovibep treatment (75/225/600mg single infusion). There were 2 COVID-19 r.. | ||
Aug 9 2022 |
et al., Annals of Internal Medicine, doi:10.7326/M22-1503 | Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 |
| 28% lower mortality (p=0.16), 11% lower combined mortality/hospitalization (p=0.47), 6% improved recovery (p=0.55), and 7% higher hospital discharge (p=0.46). RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg. Long-term results are reported in [Mourad] | ||
Nov 16 2021 |
, Press Release | Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19 |
| News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized. | ||
Feb 3 2021 |
et al., bioRxiv, doi:10.1101/2021.02.03.429164 | Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants |
| In Silico, In Vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.